Blue Barn Wealth LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

Blue Barn Wealth LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,024 shares of the company’s stock, valued at approximately $204,000.

A number of other large investors also recently made changes to their positions in the company. Clearstead Advisors LLC lifted its position in AstraZeneca by 15.5% in the 3rd quarter. Clearstead Advisors LLC now owns 1,209 shares of the company’s stock worth $82,000 after buying an additional 162 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its stake in shares of AstraZeneca by 0.3% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock valued at $4,167,000 after purchasing an additional 164 shares in the last quarter. Gradient Investments LLC grew its holdings in shares of AstraZeneca by 2.4% during the 3rd quarter. Gradient Investments LLC now owns 7,259 shares of the company’s stock valued at $492,000 after purchasing an additional 169 shares during the last quarter. Drive Wealth Management LLC raised its position in AstraZeneca by 4.5% in the 4th quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock worth $263,000 after purchasing an additional 170 shares during the period. Finally, Glenview Trust co lifted its stake in AstraZeneca by 3.8% in the third quarter. Glenview Trust co now owns 4,724 shares of the company’s stock worth $320,000 after purchasing an additional 174 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Morgan Stanley started coverage on AstraZeneca in a report on Tuesday, January 23rd. They issued an “overweight” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.00.

AstraZeneca Trading Up 0.7 %

Shares of AZN stock traded up $0.56 during trading hours on Tuesday, reaching $76.32. The company’s stock had a trading volume of 6,659,937 shares, compared to its average volume of 6,361,413. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $236.63 billion, a P/E ratio of 37.41, a P/E/G ratio of 1.39 and a beta of 0.47. The firm’s fifty day simple moving average is $68.58 and its 200 day simple moving average is $66.42. AstraZeneca PLC has a one year low of $60.47 and a one year high of $76.80.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The company had revenue of $12.02 billion for the quarter, compared to analysts’ expectations of $12.07 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.69 earnings per share. Equities research analysts expect that AstraZeneca PLC will post 4.01 EPS for the current year.

AstraZeneca Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were given a dividend of $0.965 per share. This represents a yield of 2.3%. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s payout ratio is presently 94.61%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.